Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Novo’s Diabetes Drug Demonstrates Impressive CV Safety Profile

By Ryan Bushey | September 19, 2016

Novo Nordisk’s experimental diabetes drug semaglutide hit an important milestone in a recent study.

The Danish drug maker announced its once-weekly injectable therapy significantly reduced cardiovascular risk by 26 percent in more than 3,000 patients diagnosed with type 2 diabetes, reported Reuters.

Novo previously disclosed in April that the drug was able to lower the risk of cardiovascular events, but this latest notice is the first in which the company revealed the specific numbers related to this effect.

“The reduction in cardiovascular events observed with semaglutide in SUSTAIN 6 is notable given the small study population and the short trial duration,” Dr. Steven Marso, SUSTAIN 6 investigator and the lead author for the New England Journal of Medicine publication of SUSTAIN 6, said in a statement.

Lowering the possibility of cardiovascular events, like heart attack and strokes, is important for type 2 diabetes patients because about half of deaths related to this ailment occur due to heart disease.

Novo did acknowledge in its press release that there was a higher frequency of patients taking semaglutide who experienced complications from diabetic retinopathy, which causes damage to blood vessels at the back of the eye. Also, some participants had to discontinue treatment because of gastrointestinal events.

However, Novo plans to use this data along with an expanded trial exploring the drug’s benefits to make a case for a regulatory submission in the U.S. and Europe during the final quarter of 2016, explained Reuters.

Analysts predict this drug could bring in annual sales of $2.2 billion in 2022.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE